DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
CHESTERBROOK, Pa., Feb. 28, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 7, 2018 at 8:00 am EST to review financial results as of and for the quarter and year ended December 31, 2017 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 7843918).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 7843918). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
SVP, scientific affairs and investor relations officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
